United States: FDA Announced The Opportunity To Comment On The Following Proposed Information Collections

• Waiver of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form Products and Type A Medicated Articles—21 CFR 514.1(b)(7-8) (OMB Control No. 0910-0575)—Extension
• Prominent and Conspicuous Mark of Manufacturers on Single-Use Devices

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.